Rosalind Advisors Inc. Takes Position in Fractyl Health, Inc. $GUTS

Rosalind Advisors Inc. purchased a new position in Fractyl Health, Inc. (NASDAQ:GUTS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,000,000 shares of the company’s stock, valued at approximately $7,950,000. Fractyl Health accounts for 2.8% of Rosalind Advisors Inc.’s holdings, making the stock its 17th biggest position. Rosalind Advisors Inc. owned approximately 9.94% of Fractyl Health at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Woodline Partners LP boosted its holdings in Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after acquiring an additional 165,786 shares during the period. Catalyst Funds Management Pty Ltd purchased a new stake in Fractyl Health in the second quarter worth $26,000. Qube Research & Technologies Ltd bought a new stake in shares of Fractyl Health during the second quarter worth $129,000. General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health during the second quarter worth $7,912,000. Finally, Jane Street Group LLC purchased a new stake in shares of Fractyl Health during the second quarter valued at $31,000.

Fractyl Health Stock Down 0.1%

Fractyl Health stock opened at $0.47 on Friday. The firm has a market cap of $64.34 million, a P/E ratio of -0.21 and a beta of 1.51. The business has a fifty day moving average of $1.05 and a two-hundred day moving average of $1.32. Fractyl Health, Inc. has a twelve month low of $0.38 and a twelve month high of $3.03.

Analysts Set New Price Targets

A number of research analysts have recently commented on GUTS shares. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Friday, December 19th. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $8.00 to $2.00 in a research report on Thursday, January 29th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Tuesday, December 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $5.40.

Fractyl Health Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.